Table 1 Baseline characteristics of the 42 AML patients
Characteristic | |
|---|---|
Total number of patients | 42 |
Median age, years (range) | 40 (16–60) |
Gender | |
Male | 23 (54.8%) |
Female | 19 (45.2%) |
ECOG | 1 (0–1) |
Baseline WBC (× 109/L) Median (IQR) | 8.0 (0.29–201) |
Baseline platelet count, (× 109/L) Median (IQR) | 37 (6–812) |
ELN 2022 risk group | |
Favorable | 17 (40.5%) |
Intermediate | 6 (14.3%) |
Adverse | 19 (45.2%) |
ELN 2017 risk group | |
Favorable | 18 (42.9%) |
Intermediate | 10 (23.8%) |
Adverse | 14 (33.3%) |
Cytogenetic risk category | |
Favorable | 11 (26.2%) |
Intermediate | 22 (52.4%) |
Adverse | 8 (19%) |
No mitosis | 1 (2.4%) |
Selected molecular mutations | |
FLT3-ITD | 13 (30.9%) |
DNMT3A | 9 (21.4%) |
NPM1 | 7 (16.7%) |
TET2 | 6 (14.3%) |
RUNX1 | 6 (14.3%) |
BCOR | 6 (14.3%) |
KIT | 6 (14.3%) |
RAS | 6 (14.3%) |
CEBPA (B-zip) | 5 (11.9%) |
FLT3-TKD | 4 (9.5%) |
IDH2 | 4 (9.5%) |
PHF6 | 4 (9.5%) |
WT1 | 4 (9.5%) |
ASXL1 | 3 (7.1%) |
IDH1 | 3 (7.1%) |
PTPN11 | 3 (7.1%) |
SRSF2 | 2 (4.8%) |
JAK2 | 2 (4.8%) |
EZH2 | 1 (2.4%) |
STAG2 | 1 (2.4%) |
CSF3R | 1 (2.4%) |